Capecitabine
- Generic Name
- Capecitabine
- Brand Names
- Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22FN3O6
- CAS Number
- 154361-50-9
- Unique Ingredient Identifier
- 6804DJ8Z9U
- Background
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
- Indication
Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer. For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy. For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease. Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.
- Associated Conditions
- Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer
- Associated Therapies
- Chemotherapy
A Study of Varlitinib in Japanese Subjects With Advanced or Metastatic Solid Tumours
- Conditions
- Advanced or Metastatic Biliary Tract CancerAdvanced or Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2017-03-17
- Last Posted Date
- 2018-06-28
- Lead Sponsor
- ASLAN Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT03082053
- Locations
- 🇯🇵
ASLAN Selected sites, Tokyo, Japan
Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma
- Conditions
- Biliary Tract CancerAdjuvant ChemotherapyCapecitabineGemcitabineCholangiocarcinomaCisplatin
- Interventions
- First Posted Date
- 2017-03-14
- Last Posted Date
- 2022-12-06
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 101
- Registration Number
- NCT03079427
- Locations
- 🇰🇷
Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of
Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer
- Conditions
- Stage III Pancreatic Cancer AJCC v6 and v7Pancreatic AdenocarcinomaStage IB Pancreatic Cancer AJCC v6 and v7Stage IIA Pancreatic Cancer AJCC v6 and v7Recurrent Pancreatic CarcinomaStage I Pancreatic Cancer AJCC v6 and v7Stage IA Pancreatic Cancer AJCC v6 and v7Stage IV Pancreatic Cancer AJCC v6 and v7Stage II Pancreatic Cancer AJCC v6 and v7Stage IIB Pancreatic Cancer AJCC v6 and v7
- Interventions
- Drug: CapecitabineDrug: FluorouracilOther: Laboratory Biomarker AnalysisOther: Pharmacological StudyRadiation: Stereotactic Body Radiation TherapyDrug: Zoledronic Acid
- First Posted Date
- 2017-03-08
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 44
- Registration Number
- NCT03073785
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004
- Conditions
- Colorectal TumorsColorectal NeoplasmsColorectal CancerColorectal CarcinomaColorectal Adenocarcinoma
- Interventions
- First Posted Date
- 2017-02-13
- Last Posted Date
- 2021-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT03050814
- Locations
- 🇺🇸
Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
🇺🇸National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery
- Conditions
- Stage IIIB Breast CancerEstrogen Receptor NegativeHER2/Neu NegativeStage III Breast CancerTriple-Negative Breast CarcinomaProgesterone Receptor NegativeRecurrent Breast CarcinomaStage IIIA Breast CancerStage IV Breast CancerStage IIIC Breast Cancer
- Interventions
- First Posted Date
- 2017-02-07
- Last Posted Date
- 2020-07-13
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 30
- Registration Number
- NCT03044730
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸Northwestern Lake Forest Hospital, Lake Forest, Illinois, United States
Multicenter, Prospective, RCT：Investigation of Combined Modality Therapy for Locally Advanced Mid/Low Rectal Cancer.
- Conditions
- Rectal Cancer, AdenocarcinomaNeoadjuvant Chemoradiation
- Interventions
- Other: non-NCRTOther: NCRTProcedure: TEMProcedure: radical resectionDrug: capecitabine with oxaliplatinDrug: capecitabine
- First Posted Date
- 2017-02-03
- Last Posted Date
- 2017-02-03
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 1200
- Registration Number
- NCT03042000
A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer
- Conditions
- Liver CancerHepatocellular Cancer
- Interventions
- First Posted Date
- 2017-01-20
- Last Posted Date
- 2017-04-13
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 4
- Registration Number
- NCT03026803
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Sequential Neo-adjuvant Chemotherapy Followed by Capecitabine Vs. Conventional Adjuvant Chemotherapy in Breast Cancer
- Conditions
- Breast Neoplasm Female
- Interventions
- Procedure: Neo-adjuvant ChemotherapyDrug: Capecitabine
- First Posted Date
- 2017-01-05
- Last Posted Date
- 2017-01-10
- Lead Sponsor
- The First Hospital of Jilin University
- Target Recruit Count
- 1588
- Registration Number
- NCT03011060
- Locations
- 🇨🇳
the First Hospital of Jilin University, Changchun, Jilin, China
Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer
- Conditions
- Metastatic Cancer
- Interventions
- First Posted Date
- 2017-01-04
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Immodulon Therapeutics Ltd
- Target Recruit Count
- 2
- Registration Number
- NCT03009058
- Locations
- 🇫🇷
Centre Léon Bérard, Dpt Medecine & INSERM, Lyon, France
🇫🇷Gustave Roussy Cancer Center, Villejuif, France
🇬🇧St George's University of London, Institute of Infection and Immunity, London, United Kingdom
Study of Adjuvant ONO-4538 With Resected Gastric Cancer
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2016-12-30
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 800
- Registration Number
- NCT03006705
- Locations
- 🇨🇳
Anhui Province Clinical Site, Anhui Province, China
🇨🇳Zhejiang Province Clinical Site, Zhejiang Province, China
🇯🇵Nagano Clinical Site, Saku, Nagano, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.